Menu

Bogus Isomer Vendors Identified

Pharma company publishes a list of 17 companies known to have sold the incorrect isomer of the kinase inhibitor bosutinib.

May 25, 2012
Sabrina Richards

WIKIMEDIA COMMONS, TIBOR KADEK

Pharmaceutical company PKC Pharma has published list of companies known to have sold the incorrect isomer of the kinase inhibitor bosutinib, which researchers are studying as a potential chemotherapeutic agent. As The Scientist reported earlier this month (see Mismarketed Chemical Causes Concern), inconsistent NMR spectra alerted the biochemical community that an incorrect isomer of bosutinib had entered the marketplace. PKC Pharma, after being notified that its own bosutinib was actually the incorrect isomer, began purchasing and testing bosutinib from different vendors to learn how many may have unwittingly sold an incorrect form of bosutinib. This week (May 23), the company listed 17 vendors on its website that it says sold the incorrect isomer, verified by several tests including proton NMR.

PKC Pharma, which had distributed bostunib bought from other suppliers, will seek refunds from companies that supplied the incorrect isomer, said President Paul Driedger, and has already sent letters offering refunds or replacements to PKC Pharma’s customers. One company on PKC Pharma’s list, Selleckchem, has already switched to the correct isomer. General Manager Graham Dong said that to his knowledge, any incorrect isomer purchased had already been replaced with the correct bosutinib isomer synthesized by Selleckchem. Although companies may not welcome appearing on PKC Pharma’s list, “We’re willing to stand by our data,” said Driedger, who noted that his company had also produced an X-ray crystallography of the incorrect isomer, verified by three experts.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.